Adrienne G. Waks - Concepedia

Author

Adrienne G. Waks

Also Known As

A Waks, A.G. Waks, Abramson, Vandana G, Adrienne G Waks, Adrienne G. Waks, Adrienne Gropper Waks, Adrienne Waks, Bueno-Muiño, C, Rubio, T.

214

Publications

8.3K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Brigham and Women's Hospital Massachusetts General Hospital Broad Institute

About

Adrienne G. Waks is an author at Dana-Farber Cancer Institute specializing in breast cancer, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.9K
2	Health Sciences	3	3	1.1K
3	Cell Biology	3	3	1.3K
4	Immunology	2	2	103
5	Engineering	1	1	15

Adrienne G. Waks

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors Viktor A. Adalsteinsson, Gavin Ha, Samuel S. Freeman, Nature Communications Metastatic TumorsPathologyTumor BiologyTumor HeterogeneityScalable Whole-exome Sequencing	2017	1K
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Seth A. Wander, Ofir Cohen, Xueqian Gong, Cancer Discovery	2020	399
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies Utthara Nayar, Ofir Cohen, Christian Kapstad, Nature Genetics Breast OncologyMedicineAcquired Her2 MutationsCancer BiologyBreast Cancer	2018	233
Breast Cancer Treatment Adrienne G. Waks, Eric P. Winer JAMA Surgical OncologyBreast OncologyMedicineCancer ManagementBreast Cancer	2019	233
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab Otto Metzger, Giuseppe Viale, Shayna Stein, Cancer Discovery	2021	222
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer Pingping Mao, Ofir Cohen, Kailey J. Kowalski, Clinical Cancer Research	2020	178
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer Adrienne G. Waks, Ofir Cohen, Bose Kochupurakkal, Annals of Oncology	2020	152
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial Sara M. Tolaney, Paolo Tarantino, Noah Graham, The Lancet Oncology Breast OncologyOncologyBreast CancerAdjuvant PaclitaxelCancer Treatment	2023	151
The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy Adrienne G. Waks, Daniel G. Stover, Jennifer L. Guerriero, Clinical Cancer Research	2019	113
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. Otto Metzger, Giuseppe Viale, Lorenzo Trippa, Journal of Clinical Oncology Breast OncologyCancer ManagementImmunologyPathologyHer2 Heterogeneity	2019	81

Page 1